Clinical Trial

Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.

Study acronym: ATD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated September 20, 2024 completion). Its status may not reflect the trial's current state.
Summary
Multicenter, retrospective-prospective, real-world observational study, with the aim of evaluating tolerability and efficacy in a population of patients treated according to clinical practice outside of studies randomized.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-15.
Trial Details
NCT Number NCT06272799
Lead Sponsor Regina Elena Cancer Institute
Conditions Breast Cancer
Enrollment 160 participants
Start Date 2022-09-20
Primary Completion 2024-09-20 (estimated)
Study Completion 2024-09-20 (estimated)
Updated on ClinicalTrials.gov 2024-09-19